ISPO

Published in Cancer Detection and Prevention 1993; 17(2):289-293.

Recombinant Immunotoxins: New Therapeutic Agents for Cancer Treatment

IH Pastan, MD

Laboratory of Molecular Biology, Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 4E16, Bethesda, MD 20892

ABSTRACT: We have developed new agents for the treatment of cancer by genetically modifying Pseudomonas exotoxin. We have deleted the cell-binding region of Pseudomonas exotoxin and replaced it with various growth factors or the combining regions of antibodies in a single chain form. These new recombinant molecules are called recombinant toxins. Several different types of recombinant toxins have been produced. B3(Fv)-PE38KDEL is a recombinant toxin that kills many different adenocarcinomas and epidermoid carcinomas. The molecule is now undergoing preclinical development.

KEY WORDS: Pseudomonas exotoxin, chemotherapy .

http://www.cancerprev.org/Journal/Issues/17/2/440